Wednesday, November 18, 2026
  • Login
CEO North America
  • Home
  • News
    • Business
    • Entrepreneur
    • Industry
    • Innovation
    • Management & Leadership
  • CEO Interviews
  • Opinion
  • Technology
  • Environment
  • CEO Life
    • Art & Culture
    • Food
    • Health
    • Travel
No Result
View All Result
  • Home
  • News
    • Business
    • Entrepreneur
    • Industry
    • Innovation
    • Management & Leadership
  • CEO Interviews
  • Opinion
  • Technology
  • Environment
  • CEO Life
    • Art & Culture
    • Food
    • Health
    • Travel
No Result
View All Result
CEO North America
No Result
View All Result

CEO NA Magazine > News > U.S. to pay Pfizer nearly $2 billion for more Paxlovid courses in 2023

U.S. to pay Pfizer nearly $2 billion for more Paxlovid courses in 2023

in News
U.S. to pay Pfizer nearly $2 billion for more Paxlovid courses in 2023
Share on LinkedinShare on WhatsApp

The U.S. government agreed to pay Pfizer Inc (NYSE: PFE) nearly $2 billion for an additional 3.7 million courses of its authorized COVID-19 oral treatment, PAXLOVID™ the company said on Tuesday. The new purchase supplements the 20 million courses previously bought by the United States and delivery is planned by early 2023, Pfizer said in a statement.

PAXLOVID™ plays an important role in helping to combat COVID-19-related hospitalizations and death in high-risk patients. The oral treatment is currently authorized for conditional or emergency use in approximately 70 countries across the globe, including the United States. As of Nov. 30, Pfizer had shipped almost 37 million courses of Paxlovid to 52 countries around the world, it said in a statement. That includes all 20 million courses previously ordered by the U.S. government.

The two-drug oral treatment is currently available for free in the United States, where more than 9 million courses have been delivered to pharmacies, and patients have used over 6 million courses of the treatment, according to government data.

Pfizer is expected to top $100 billion in revenue this year, more than half of which is expected to come from its COVID business.

Tags: PfizerPfizer coronavirus vaccinePfizer vaccine

Related Posts

U.S. officials order Nvidia to stop sales of AI chips to China
News

Nvidia shares rally following earnings beat

Target aims for non-alcoholic cocktail market ahead of the holiday season
News

Target reports its strongest sales growth in five years

Huang joins top CEOs on Trump’s China trip
News

Trump arrives in China for historic Xi, Putin meeting

The IMF-World Bank meetings commence in Washington
News

IMF chief gives stark warning on global economy 

Disney’s full year earnings prove streaming is successful
News

Disney beats earnings expectations as park attendance grows

Home Depot CFO delivers strategic update as company offers cautious forecast
News

Home Depot names Richard McPhail CEO amid leadership reshuffle

Nvidia due in Supreme Court today
News

Nvidia stock falls as execs push for Huang’s return

Warren Buffett Becomes HP Top Shareholder
News

Buffett donates $5.5 billion, urges kindness in Thanksgiving letter

Eli Lilly pledges $6 billion manufacturing plant in Alabama
News

Lilly to acquire Calytrix Bio in $1.5 billion deal

Trump pardons Founder and former CEO of Binance
News

$1.2 billion in stolen Binance crypto seized by U.S.

No Result
View All Result

Recent Posts

  • AI Has Entered the Boardroom. Who’s Overseeing It?
  • ‘Grand Theft Auto VI’ could be the biggest entertainment launch in history
  • Nvidia shares rally following earnings beat
  • Target reports its strongest sales growth in five years
  • Trump arrives in China for historic Xi, Putin meeting

Archives

Categories

  • Art & Culture
  • Business
  • CEO Interviews
  • CEO Life
  • Editor´s Choice
  • Entrepreneur
  • Environment
  • Food
  • Health
  • Highlights
  • Industry
  • Innovation
  • Issues
  • Management & Leadership
  • News
  • Opinion
  • PrimeZone
  • Printed Version
  • Technology
  • Travel
  • Uncategorized

Meta

  • Log in
  • Entries feed
  • Comments feed
  • WordPress.org

  • CONTACT
  • GENERAL ENQUIRIES
  • ADVERTISING
  • MEDIA KIT
  • DIRECTORY
  • TERMS AND CONDITIONS

Advertising –
advertising@ceo-na.com

110 Wall St.,
3rd Floor
New York, NY.
10005
USA
+1 2125 9933 0330

UK
Collingwood Buildings,
38 Collingwood Street,
Newcastle Upon Tyne
NE1 1JF

  • News
  • CEO Interviews
  • Opinion
  • Technology
  • Environment
  • CEO Life

  • CONTACT
  • GENERAL ENQUIRIES
  • ADVERTISING
  • MEDIA KIT
  • DIRECTORY
  • TERMS AND CONDITIONS

Advertising –
advertising@ceo-na.com

110 Wall St.,
3rd Floor
New York, NY.
10005
USA
+1 2125 9933 0330

UK
Collingwood Buildings,
38 Collingwood Street,
Newcastle Upon Tyne
NE1 1JF

CEO North America © 2024 - Sitemap

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Home
  • News
    • Business
    • Entrepreneur
    • Industry
    • Innovation
    • Management & Leadership
  • CEO Interviews
  • Opinion
  • Technology
  • Environment
  • CEO Life
    • Art & Culture
    • Food
    • Health
    • Travel

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.